Eighteen anal cancer patients received the same drug for six months, and as a result of the treatment, the cancer was eliminated in each patient.

A small group of people with anal cancer experienced a miracle when their cancer disappeared after experimental treatment. According to the NY Times, in a tiny clinical trial, 18 patients took a drug called dostarlimab for about six months, and eventually, each of them saw their tumors disappear.

Dostarlimab is a drug with a laboratory-made molecule that acts as a substitute antibody in the human body. All 18 patients with anal cancer received the same drug. As a result of the treatment, also cancer was entirely eradicated in every patient - not detected on physical examination; endoscope; Positron emission tomography or PET scan, or MRI scan.

Dr. Louis A. Diaz J. of the Elephant Catering Memorial Cancer Center in New York said this was "the 1st time this has happened in the history of cancer." According to the New York Times, patients in clinical trials faced previous grueling treatments to eradicate their cancer, including chemotherapy, radiation, and invasive surgery that can result in the bowel, urinary, and even sexual dysfunction. Eighteen patients participated in this study and are expected to undergo it as a next step. However, to his surprise, no further treatment was required.

The results are now engaging in the medical world and speaking to the media, drg. Alan P. Venoke, a colorectal cancer specialist at the University of California, that complete remission is "unheard of" in any patient. He welcomed the research as a world first. He even noted that this was particularly impressive given that not all patients experienced significant complications from the study drug.

Separately, Memorial Sloan Kettering Cancer Center and co-author of the article, oncologist Dr. Andrea Chercek, when patients realize they are cancer-free. "There were many tears of joy," he told the New York Times.

For the study, patients took dostarlimab every three weeks for six months. They are all at the same cancer stage - cancer has developed locally in the rectum but has not spread to other organs. Now cancer researchers who have reviewed the drug have told the media the treatment looks promising, but more extensive studies are needed to see if the drug works in more patients and whether the cancer is actually in remission.